Cost-effectiveness of B-type natriuretic peptide testing

Congest Heart Fail. Jul-Aug 2008;14(4 Suppl 1):35-7. doi: 10.1111/j.1751-7133.2008.tb00009.x.

Abstract

As with any other diagnostic method, the cost-effectiveness of B-type natriuretic peptide (BNP) testing depends on the indication of its use and the specific clinical setting. The use of BNP levels, in conjunction with other clinical information, provides information that seems to be particularly helpful in the diagnosis, prognosis, and management of heart failure (HF) as well as screening for left ventricular systolic dysfunction. In the screening for asymptomatic left ventricular systolic dysfunction, BNP testing seems to be cost-effective (<$50,000 per quality-adjusted life-years gained) when used in a population with a prevalence of at least 1%. BNP testing, in fact, results in cost savings in the diagnosis of HF. Although the data are less robust, BNP seems cost-effective in the risk stratification of hospitalized HF patients when compared with echocardiography. Because BNP guidance seems to reduce the number of rehospitalizations in recently hospitalized patients with chronic HF, the use of BNP is also most likely cost-effective in this indication. For the remaining and, in part, evolving indications, further studies are needed to assess cost-effectiveness.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Cost-Benefit Analysis
  • Decision Making
  • Heart Failure, Systolic / diagnosis*
  • Heart Failure, Systolic / drug therapy
  • Heart Failure, Systolic / physiopathology
  • Humans
  • Mass Screening / economics
  • Natriuretic Peptide, Brain / economics*
  • Prognosis
  • Systole
  • Ventricular Dysfunction, Left / diagnosis*
  • Ventricular Dysfunction, Left / drug therapy
  • Ventricular Dysfunction, Left / physiopathology

Substances

  • Natriuretic Peptide, Brain